Compare ANIP & TY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIP | TY |
|---|---|---|
| Founded | 2001 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1999 | N/A |
| Metric | ANIP | TY |
|---|---|---|
| Price | $77.66 | $32.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | ★ 289.3K | 51.6K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | ★ 419.23 | N/A |
| EPS | 3.32 | ★ 4.78 |
| Revenue | ★ $206,547,000.00 | N/A |
| Revenue This Year | $21.01 | N/A |
| Revenue Next Year | $17.59 | N/A |
| P/E Ratio | $22.35 | ★ $6.68 |
| Revenue Growth | ★ 2.47 | N/A |
| 52 Week Low | $56.71 | $27.08 |
| 52 Week High | $99.50 | $35.05 |
| Indicator | ANIP | TY |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 50.38 |
| Support Level | $75.20 | $31.80 |
| Resistance Level | $77.47 | $32.09 |
| Average True Range (ATR) | 2.31 | 0.63 |
| MACD | 0.50 | 0.10 |
| Stochastic Oscillator | 82.99 | 71.98 |
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.